Alanna Lee, MD
Internal Medicine · Kansas City, KSNPI 1396743423
Payments from drug & device makers
Across 235 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$884
- Lilly USA, LLC$776
- Novo Nordisk$404
- Sunovion Pharmaceuticals Inc.$367
- Merck$337
- Novartis$262
- plus $1K from 14 others
What the payments were for
- Travel & lodging$1844%
- Food & beverage$3,99596%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $884 |
| Lilly USA, LLC | 50 | $776 |
| Novo Nordisk | 21 | $404 |
| Sunovion Pharmaceuticals Inc. | 29 | $367 |
| Merck | 22 | $337 |
| Novartis | 15 | $262 |
| GSK | 11 | $226 |
| Johnson & Johnson | 12 | $193 |
| Bristol Myers Squibb | 1 | $184 |
| Exact Sciences | 7 | $107 |
| AbbVie(2 entities) | 4 | $73 |
| Pfizer | 4 | $66 |
| Eisai Inc. | 3 | $64 |
| Abbott | 4 | $62 |
| Amgen(2 entities) | 3 | $55 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$111
How this compares
$4,179 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 122 | $155,984 |
| JardianceEmpagliflozin | 80 | $98,370 |
| FarxigaDapagliflozin Propanediol | 83 | $86,171 |
| OzempicSemaglutide | 53 | $68,177 |
| EliquisApixaban | 38 | $47,601 |
| XareltoRivaroxaban | 37 | $37,427 |
| JanuviaSitagliptin Phosphate | 23 | $32,767 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $30,598 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $29,747 |
| LinzessLinaclotide | 31 | $21,908 |
| MounjaroTirzepatide | 20 | $21,198 |
| EntrestoSacubitril/Valsartan | 12 | $20,741 |
| TradjentaLinagliptin | 12 | $15,460 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $14,943 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $13,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $776 | $177,182142 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $884 | $129,764160 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $30 | $121,644105 claims |
| Novo NordiskOzempic | $404 | $68,17753 claims |
| PfizerEliquis | $66 | $47,60138 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $226 | $44,69148 claims |
| Johnson & JohnsonXarelto | $193 | $37,42737 claims |
| MerckJanuvia | $337 | $32,76723 claims |
| AbbVieLinzess | $73 | $21,90831 claims |
| NovartisEntresto | $262 | $20,74112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Kansas City
- Mark HamblinKansas City$5.2M
- Leslie SpikesKansas City$4.5M
- Shadi HamdehKansas City$1.1M
- Kyle WorkKansas City$863K
- Lucas PittsKansas City$314K
- Aaron RohrKansas City$136K
- Kyle JanssonKansas City$95K
- Lewis SatterwhiteKansas City$49K
- Martin KankamLeavenworth$63.4M
- Katherine WillinghamTopeka$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.